Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
TRMT6 CRISPR/Cas9 KO Plasmid (h): sc-412224
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- TRMT6 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the TRMT6 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: TRMT6 Antibody (F-3): sc-271752
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
TRMT6 CRISPR/Cas9 KO Plasmid (h) | sc-412224 | 20 µg | $397.00 |
Overview
TRMT6 encodes the catalytic subunit of the tRNA (adenine(58)-N1)-methyltransferase complex that partners with TRMT61A to install the conserved m1A58 modification in cytosolic tRNAs. This RNA modification supports tRNA structural stability, accurate decoding, and efficient translation, linking TRMT6 activity to proteostasis and cellular stress responses. Perturbation of tRNA methylation can disrupt global translation programs and has been associated with altered proliferation and genome maintenance pathways in multiple model systems. TRMT6 is therefore studied in the context of RNA epitranscriptomic regulation, translational control, and disease-relevant changes in cell growth and stress adaptation.
TRMT6 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the TRMT6 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the TRMT6 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the TRMT6 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish TRMT6 protein expression.
This CRISPR knockout system enables efficient generation of TRMT6-deficient cell models for investigation of TRMT6 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting TRMT6 exon(s) critical for TRMT6 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple TRMT6 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by TRMT6 CRISPR/Cas9 KO Plasmid (h) and TRMT6 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the TRMT6 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by TRMT6 HDR Plasmid (h) and TRMT6 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by TRMT6 homology arms to support homology-directed repair at defined TRMT6 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.